Browse Category

FDA Approval News 26 September 2025 - 25 November 2025

Merck (MRK) Stock Soars on FDA Keytruda Approval and Wells Fargo Upgrade – 25 November 2025

Merck & Co., Inc. (NYSE: MRK) is back in the market’s spotlight this Tuesday, with the pharmaceutical giant’s shares extending a powerful rally fuelled by fresh regulatory wins and a major Wall Street upgrade. As of early-afternoon trading on 25

25 November 2025

Apellis’ $458M Shocker: FDA Win, Analyst Buzz & 20% Stock Whiplash

Blockbuster Quarter Meets Stock Turbulence Apellis Pharmaceuticals, a biotech focused on complement-mediated diseases gurufocus.com, delivered standout financial results for the third quarter of 2025 – yet its stock took a beating. The company reported Q3 revenue of $458.6 million, more than

30 October 2025

Biotech · FDA Approval · Investment · Pharma News · Stock Market

Psychedelic Biotech Rally: Atai Life Sciences Stock Soars 18% on FDA Breakthrough and $130M Fundraise

Stock Surge & Analyst Reaction Atai shares exploded higher on Oct. 17, 2025. Investors bid the stock up ~17.7%, closing at roughly $6.45 ts2.tech (versus ~$5.48 offering price). In after-hours trading it briefly touched ~$6.86 ts2.tech. This rally follows a

18 October 2025

Biotech · FDA Approval · Investments · NASDAQ:ATAI · Psychedelics · Stock Market

Achieve Life Sciences Skyrockets on FDA Boost – Is This Nicotine Addiction Breakthrough a Game Changer?

Stock Price Surge & Recent Performance Achieve Life Sciences stock exploded higher on the FDA news, reflecting growing optimism around cytisinicline’s prospects. In pre-market trading on Oct. 17, ACHV jumped about 22.7% after the company revealed it received a rare

17 October 2025

Biotechnology · FDA Approval · Health News · Medical Breakthroughs · NASDAQ:ACHV · Nicotine Addiction

Spruce Biosciences Skyrockets on FDA Breakthrough – Will SPRB’s Rally Last or Fade?

Spruce Biosciences (SPRB) Skyrockets 1,300% on FDA Breakthrough – Inside the Stock Surge, Pipeline & Outlook (Oct 2025)

Stock Performance & Financial Metrics (as of Oct 7, 2025) Spruce Biosciences’ stock chart for 2025 looks like a hockey stick – mostly flat/down all year and then vertical in October. On Monday, Oct 6, SPRB opened around $8.60 and

7 October 2025

Biotechnology · FDA Approval · Investment Analysis · Pharma News · Stock Market

Crinetics (CRNX) Stock Skyrockets on FDA Approval – Full 2025 Investor Update

Stock Price Performance (YTD & Recent) Crinetics stock has been volatile but trending upward in 2025, with the recent FDA catalyst propelling it sharply higher. On September 26, 2025, CRNX closed around $45–$46, up roughly +28% in a single day

26 September 2025

Biotech · FDA Approval · Investors · NASDAQ:CRNX · Pharmaceuticals · Stock Market · Stocks

Go toTop